Technical Analysis for ABEO - Abeona Therapeutics Inc.

Grade Last Price % Change Price Change
C 6.99 -19.00% -1.64
ABEO closed down 19.0 percent on Monday, March 18, 2024, on 3.92 times normal volume.
Earnings due: Mar 27
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Volume Surge Other 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Pocket Pivot Bullish Swing Setup -19.00%
Wide Bands Range Expansion -19.00%
MACD Bearish Signal Line Cross Bearish -14.13%
Boomer Buy Setup Bullish Swing Setup -14.13%
Inside Day Range Contraction -14.13%
Wide Bands Range Expansion -14.13%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 12 hours ago
20 DMA Support about 15 hours ago
2x Volume Pace about 16 hours ago
1.5x Volume Pace about 16 hours ago
3x Volume Pace about 16 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Abeona Therapeutics Inc. Description

Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Biology Emerging Technologies Rare Diseases Molecular Biology Gene Therapy Genetics Genetic Engineering Anemia CRISPR Genome Editing Adeno Associated Virus Cas9 Severe And Rare Diseases Blood Diseases Fanconi Anemia

Is ABEO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.01
52 Week Low 2.34
Average Volume 356,346
200-Day Moving Average 4.67
50-Day Moving Average 6.20
20-Day Moving Average 7.64
10-Day Moving Average 8.13
Average True Range 0.73
RSI (14) 47.37
ADX 50.06
+DI 26.09
-DI 19.83
Chandelier Exit (Long, 3 ATRs) 6.81
Chandelier Exit (Short, 3 ATRs) 8.19
Upper Bollinger Bands 8.96
Lower Bollinger Band 6.32
Percent B (%b) 0.25
BandWidth 34.58
MACD Line 0.54
MACD Signal Line 0.65
MACD Histogram -0.1072
Fundamentals Value
Market Cap 173.17 Million
Num Shares 24.8 Million
EPS -1.37
Price-to-Earnings (P/E) Ratio -5.10
Price-to-Sales 45.13
Price-to-Book 6.97
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.92
Resistance 3 (R3) 9.03 8.48 8.60
Resistance 2 (R2) 8.48 7.99 8.43 8.49
Resistance 1 (R1) 7.74 7.69 7.46 7.63 8.39
Pivot Point 7.19 7.19 7.06 7.14 7.19
Support 1 (S1) 6.45 6.70 6.18 6.35 5.59
Support 2 (S2) 5.90 6.40 5.85 5.49
Support 3 (S3) 5.16 5.90 5.38
Support 4 (S4) 5.06